{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:18:13Z","timestamp":1782256693865,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Targeted therapies against programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC) have revolutionized the management in recent years. There is paucity of data on the significance of PD-L1 expression in NSCLC from India. We aimed to study the prevalence of PD-L1 expression and its relation with different clinico-pathological parameters in advanced NSCLC from a tertiary care center in Eastern India.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All consecutive patients with advanced NSCLC diagnosed from January 2020 to December 2021 were prospectively evaluated for PD-L1 expression in formalin fixed-paraffin embedded tumor tissue specimens using immunohistochemistry analysis. A PD-L1 expression of\u2009&lt;\u20091%, 1\u201349%, and\u2009\u2265\u200950% were considered negative, low, and high expression positive respectively, and association with various parameters was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 94 patients (mean age 59.6\u2009\u00b1\u200914\u00a0years and 63.8% males), PD-L1 positivity was seen in 42 (44.7%) patients, with low positivity (1\u201349%) in 29 patients and high positivity (\u2265\u200950%) in 13 patients. Epidermal Growth Factor Receptor (EGFR) mutations were seen in 28 patients (29.8%). There were no significant differences in PD-L1 positivity with respect to gender, age, and molecular mutation status. PD-L1 positivity was significantly associated with tobacco use (<jats:italic>p<\/jats:italic>\u2009=\u20090.04), advanced tumor stage (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and higher nodal stage (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Median overall survival in the cohort was 17\u00a0months and it was not significantly different between the PD-L1 positive and negative groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Forty-five percent of advanced NSCLC patients in our cohort showed positive PD-L1 expression and it is associated with tobacco use and aggressive tumor characteristics.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-024-00207-5","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T13:03:13Z","timestamp":1706533393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center"],"prefix":"10.1186","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-522X","authenticated-orcid":false,"given":"Sindhu","family":"Kilaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya Surath","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalatendu","family":"Moharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debahuti","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya Sundar G.","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adyakinkar","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spoorthy","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Devaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanashyam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"207_CR1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u201334.","journal-title":"J Exp Med"},{"key":"207_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"207_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"207_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"207_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350.","journal-title":"Lancet"},{"key":"207_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/labinvest.2013.130","volume":"94","author":"V Velcheti","year":"2014","unstructured":"Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107\u201316.","journal-title":"Lab Invest"},{"key":"207_CR7","unstructured":"VENTANA PD-L1 (SP263) Assay (CE IVD). In: Diagnostics. https:\/\/diagnostics.roche.com\/in\/en_gb\/products\/tests\/ventana-pd-l1-_sp263-assay2.html. Accessed 9 Mar 2022"},{"key":"207_CR8","doi-asserted-by":"publisher","first-page":"e0183023","DOI":"10.1371\/journal.pone.0183023","volume":"12","author":"M Ilie","year":"2017","unstructured":"Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P. Use of the 22C3 anti\u2013PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One. 2017;12:e0183023.","journal-title":"PLoS One"},{"key":"207_CR9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","volume":"33","author":"SN Gettinger","year":"2015","unstructured":"Gettinger SN, Horn L, Gandhi L, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33:2004\u201312.","journal-title":"J Clin Oncol"},{"key":"207_CR10","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1200\/jco.2015.33.15_suppl.8025","volume":"33","author":"SN Gettinger","year":"2015","unstructured":"Gettinger SN, Hellmann MD, Shepherd FA, et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. JCO. 2015;33:8025\u20138025.","journal-title":"JCO"},{"key":"207_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ejca.2014.01.018","volume":"50","author":"C-Y Yang","year":"2014","unstructured":"Yang C-Y, Lin M-W, Chang Y-L, Wu C-T, Yang P-C. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014;50:1361\u20139.","journal-title":"Eur J Cancer"},{"key":"207_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41379-019-0339-0","volume":"33","author":"BG Skov","year":"2020","unstructured":"Skov BG, R\u00f8rvig SB, Jensen THL, Skov T. The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. Mod Pathol. 2020;33:109\u201317.","journal-title":"Mod Pathol"},{"key":"207_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208\u201322.","journal-title":"J Thorac Oncol"},{"key":"207_CR14","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13:1302\u201311.","journal-title":"J Thorac Oncol"},{"key":"207_CR15","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.21037\/jtd.2019.10.80","volume":"11","author":"Y Jin","year":"2019","unstructured":"Jin Y, Shen X, Pan Y, Zheng Q, Chen H, Hu H, Li Y. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. J Thorac Dis. 2019;11:4591\u2013601.","journal-title":"J Thorac Dis"},{"key":"207_CR16","doi-asserted-by":"publisher","first-page":"E824","DOI":"10.3390\/ijms20040824","volume":"20","author":"K Pawelczyk","year":"2019","unstructured":"Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, Podhorska-Okolow M, Dziegiel P, Nowinska K. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. Int J Mol Sci. 2019;20:E824.","journal-title":"Int J Mol Sci"},{"key":"207_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.anndiagpath.2017.07.001","volume":"31","author":"AG Vallonthaiel","year":"2017","unstructured":"Vallonthaiel AG, Malik PS, Singh V, Kumar V, Kumar S, Sharma MC, Mathur S, Arava S, Guleria R, Jain D. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. Ann Diagn Pathol. 2017;31:56\u201361.","journal-title":"Ann Diagn Pathol"},{"key":"207_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/lungindia.lungindia_488_19","volume":"37","author":"M Kumar","year":"2020","unstructured":"Kumar M, Guleria B, Swamy S, Soni S. Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. Lung India. 2020;37:145\u201350.","journal-title":"Lung India"},{"key":"207_CR19","doi-asserted-by":"publisher","first-page":"ix153","DOI":"10.1093\/annonc\/mdy425.009","volume":"29","author":"KR Domadia","year":"2018","unstructured":"Domadia KR, Batra U, Jain P, Sharma M, Gupta S, Bothra SJ, Pasricha S, Chaudhari K, Vishwakarma G. Retrospective evaluation of PD-L1 expression in tumor tissue of patients with lung carcinoma and correlation with clinical and demographical data from a tertiary care institute of northern India. Annals of Oncology. 2018;29:ix153.","journal-title":"Annals of Oncology"},{"key":"207_CR20","doi-asserted-by":"publisher","first-page":"153497","DOI":"10.1016\/j.prp.2021.153497","volume":"228","author":"E Jain","year":"2021","unstructured":"Jain E, Sharma S, Aggarwal A, et al. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective. Pathol Res Pract. 2021;228:153497.","journal-title":"Pathol Res Pract"},{"key":"207_CR21","first-page":"774","volume":"12","author":"Q Chen","year":"2019","unstructured":"Chen Q, Fu Y-Y, Yue Q-N, Wu Q, Tang Y, Wang W-Y, Wang Y-S, Jiang L-L. Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer. Int J Clin Exp Pathol. 2019;12:774\u201386.","journal-title":"Int J Clin Exp Pathol"},{"key":"207_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.lungcan.2021.09.011","volume":"161","author":"K Takamochi","year":"2021","unstructured":"Takamochi K, Hara K, Hayashi T, Kohsaka S, Takahashi F, Suehara Y, Suzuki K. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Lung Cancer. 2021;161:163\u201370.","journal-title":"Lung Cancer"},{"key":"207_CR23","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.21037\/jtd.2017.08.61","volume":"9","author":"Y Pan","year":"2017","unstructured":"Pan Y, Zheng D, Li Y, et al. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. J Thorac Dis. 2017;9:2579\u201386.","journal-title":"J Thorac Dis"},{"key":"207_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cncy.22140","volume":"127","author":"P Mei","year":"2019","unstructured":"Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: association with clinicopathologic features and molecular alterations. Cancer Cytopathol. 2019;127:447\u201357.","journal-title":"Cancer Cytopathol"},{"key":"207_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","volume":"89","author":"WA Cooper","year":"2015","unstructured":"Cooper WA, Tran T, Vilain RE, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015;89:181\u20138.","journal-title":"Lung Cancer"},{"key":"207_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jtho.2016.12.026","volume":"12","author":"D Rangachari","year":"2017","unstructured":"Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 \u226550% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017;12:878\u201383.","journal-title":"J Thorac Oncol"},{"key":"207_CR27","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.3390\/ijms20194794","volume":"20","author":"SE Lee","year":"2019","unstructured":"Lee SE, Kim YJ, Sung M, Lee M-S, Han J, Kim HK, Choi Y-L. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. Int J Mol Sci. 2019;20:4794.","journal-title":"Int J Mol Sci"},{"key":"207_CR28","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.2147\/OTT.S156421","volume":"11","author":"B Li","year":"2018","unstructured":"Li B, Huang X, Fu L. Impact of smoking on efficacy of PD-1\/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. Onco Targets Ther. 2018;11:3691\u20136.","journal-title":"Onco Targets Ther"},{"key":"207_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/030089161209800612","volume":"98","author":"Y Chen","year":"2012","unstructured":"Chen Y, Mu C-Y, Huang J-A. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012;98:751\u20135.","journal-title":"Tumori"},{"key":"207_CR30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355\u201363.","journal-title":"Cancer Discov"},{"key":"207_CR31","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","volume":"25","author":"K Azuma","year":"2014","unstructured":"Azuma K, Ota K, Kawahara A, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25:1935\u201340.","journal-title":"Ann Oncol"},{"key":"207_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol. 2015;10:910\u201323.","journal-title":"J Thorac Oncol"},{"key":"207_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bjc.2014.555","volume":"112","author":"A D\u2019Incecco","year":"2015","unstructured":"D\u2019Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95\u2013102.","journal-title":"Br J Cancer"},{"key":"207_CR34","doi-asserted-by":"publisher","first-page":"10255","DOI":"10.1038\/s41598-017-10925-7","volume":"7","author":"M Zhang","year":"2017","unstructured":"Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017;7:10255.","journal-title":"Sci Rep"},{"key":"207_CR35","doi-asserted-by":"publisher","first-page":"14209","DOI":"10.18632\/oncotarget.3694","volume":"6","author":"Y Tang","year":"2015","unstructured":"Tang Y, Fang W, Zhang Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 2015;6:14209\u201319.","journal-title":"Oncotarget"},{"key":"207_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000458412","volume":"92","author":"S Igawa","year":"2017","unstructured":"Igawa S, Sato Y, Ryuge S, et al. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. Oncology. 2017;92:283\u201390.","journal-title":"Oncology"},{"key":"207_CR37","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.18632\/oncotarget.23969","volume":"9","author":"B Lan","year":"2018","unstructured":"Lan B, Ma C, Zhang C, Chai S, Wang P, Ding L, Wang K. Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. Oncotarget. 2018;9:7684\u201399.","journal-title":"Oncotarget"},{"key":"207_CR38","doi-asserted-by":"publisher","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","volume":"10","author":"LH Schmidt","year":"2015","unstructured":"Schmidt LH, K\u00fcmmel A, G\u00f6rlich D, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One. 2015;10:e0136023.","journal-title":"PLoS One"},{"key":"207_CR39","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.cllc.2015.02.002","volume":"16","author":"C Lin","year":"2015","unstructured":"Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clin Lung Cancer. 2015;16:e25-35.","journal-title":"Clin Lung Cancer"},{"key":"207_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/OTT.S59959","volume":"7","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014;7:567\u201373.","journal-title":"Onco Targets Ther"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-024-00207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-024-00207-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-024-00207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:34:37Z","timestamp":1706574877000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-024-00207-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1186\/s43046-024-00207-5","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"18 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee (IMS and SUM Hospital, SOA University, Bhubaneswar- IEC registration no: ECR\/627\/Inst\/OR\/2014\/RR-20); dated 13th Feb 2021: DMR\/IMS.SH\/SOA\/180471\/2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of clinical details was obtained from the patients\u2019 relatives\/next of kin at the time of enrolment into the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}